10 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Systemic mastocytosis is a clonal disease of mast cells, the immune cells that release histamine; almost every case is driven by a single mutation in the KIT gene. KIT-blocking pills now shrink the mast cell burden and ease symptoms; in the aggressive forms most patients respond, in trials with no comparison arm. Most patients have the indolent form, where the goal is symptom control.
Systemic mastocytosis (SM) is a myeloid neoplasm defined by multifocal mast cell infiltrates in marrow or other organs, with KIT D816V present in about nine of ten patients. WHO 2022 divides it into indolent SM (ISM; the majority, with skin lesions, mediator symptoms and anaphylaxis risk but near-normal life expectancy), smouldering SM, and advanced SM (AdvSM), comprising aggressive SM, mast cell leukaemia and SM with an associated haematological neoplasm (SM-AHN), where the associated CMML, MDS or AML often decides outcome. Diagnosis uses serum tryptase (with correction for hereditary alpha-tryptasaemia), high-sensitivity KIT D816V PCR in peripheral blood, and marrow biopsy with CD25/CD30 mast cell immunophenotyping; additional mutations (SRSF2, ASXL1, RUNX1, the S/A/R panel) mark high-risk disease.
Treatment is stratified. In ISM, antihistamines, cromolyn, omalizumab, epinephrine autoinjectors and trigger avoidance manage mediator symptoms; osteoporosis is treated. The 2023 US approval of avapritinib for ISM rested on PIONEER, in which 25 mg daily lowered the total symptom score by 15.6 points against 9.2 with placebo at 24 weeks and at least halved serum tryptase in 54% of patients against none; whether it changes the long-term course is not yet known. In AdvSM, midostaurin (2017; multikinase KIT inhibitor, responses in 60 percent in the single-arm pivotal trial) was approved in 2017, four years before avapritinib (the US imatinib label covers only aggressive disease without the D816V mutation), and avapritinib (2021; PATHFINDER and EXPLORER, single-arm trials of selective KIT D816V inhibition, with responses in 57 percent of 53 evaluable patients in the US label, including complete remissions) is now the preferred first-line agent for patients with platelets above 50 x 10^9/L. Cladribine remains an option, interferon is historic, and allogeneic transplant is used for mast cell leukaemia or SM-AHN with high-risk associated neoplasms. Next-generation KIT D816V inhibitors, bezuclastinib (Summit and Apex trials) and elenestinib (Harbor), aim for equal efficacy with less intracranial bleeding and cognitive toxicity; neither had a US label when openFDA was checked on 18 November 2026.
| Setting | Approach | Guideline |
|---|---|---|
| Indolent SM, symptomatic | H1 and H2 antihistamines, cromolyn, leukotriene antagonists, omalizumab for anaphylaxis, epinephrine autoinjector, bone protection; avapritinib 25 mg daily to start for moderate to severe symptoms uncontrolled by these (PIONEER); the US label advises against it when platelets are below 50 x 10^9/L. | NCCN Category 2A |
| Advanced SM, first line | Avapritinib 200 mg daily (platelets above 50 x 10^9/L) as preferred agent; midostaurin as alternative or where platelets are low. | NCCN Category 2A (preferred: avapritinib) |
| Advanced SM, subsequent lines | Switch between avapritinib and midostaurin; cladribine; clinical trials (bezuclastinib, elenestinib); allogeneic transplant for mast cell leukaemia or high-risk SM-AHN. | not mapped |
| SM-AHN | Treat the dominant component: KIT inhibitor for mast cell burden plus the standard therapy for the associated CMML, MDS or AML (hypomethylating agents, intensive chemotherapy, transplant). | not mapped |